MedTrace Logo

Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

NCT04558502 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 339

Last updated 2022-01-13

No results posted yet for this study

Summary

Although,bismuth-containing quadruple therapy has been highly recommended as first-line treatment regimen for H.pylori infection,it also has its problems and limitations in China.The primary resistance rates of metronidazole,clarithromycin and levofloxacin are all high in China.Besides that,tetracycline cannot be obtained and its complicated administration (four times daily) easily reduce patient compliance. In this study, we proposed to evaluate the eradication rate, safety, and compliance of a minocycline-based bismuth quadruple regimen.

Conditions

  • Helicobacter Pylori Eradication

Interventions

DRUG

Minocycline hydrochloride capsule

Antibiotic for H. pylori eradication

DRUG

Clarithromycin

Antibiotic for H. pylori eradication

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

DRUG

colloidal bismuth pectin

Gastric mucosal protective drug with anti-H. pylori effect

DRUG

esomeprazole

Proton pump inhibitor

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Qin Du, master · 2nd Affiliated Hospital,School of Medicine,Zhejiang University,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2022-06-05
Completion
2022-12-05

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04558502 on ClinicalTrials.gov